Linzess linaclotide: Phase II started

Ironwood and Actavis began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 145 or 290 Ug oral Linzess once daily for 8 weeks in about 240 adult patients receiving stable opioid treatment for chronic non-cancer pain. The partners market Linzess in the U.S. for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). ...